Table 2.
Baseline patient characteristics, extent of exposure to delgocitinib ointment and concomitant use of topical corticosteroids
| QBA4‐2 (n = 352) | Pooled safety population (n = 506) | |
|---|---|---|
| Age (years) | 33.0 (11.1) | 32.6 (10.8) |
| Sex, n (%) | ||
| Men | 223 (63.4) | 318 (62.8) |
| Women | 129 (36.6) | 188 (37.2) |
| Duration of AD (years) | 23.9 (12.2) | 24.2 (11.7) |
| mEASI score | 8.8 (4.9) | 10.5 (5.6) |
| IGA score, n (%) | ||
| 0 (clear), 1 (almost clear) | 0 | 2 (0.4) |
| 2 (mild) | 110 (31.3) | 115 (22.7) |
| 3 (moderate) | 215 (61.1) | 304 (60.1) |
| 4 (severe) | 27 (7.7) | 85 (16.8) |
| Pruritus NRS score | 4.7 (2.0) | 4.8 (2.0) |
| Percentage of BSA affected by AD | 19.6 (6.9) | 21.1 (7.6) |
| Exposure to delgocitinib ointment | ||
| Exposure duration (days) | 286.7 (118.4) | 251.3 (114.5) |
| Amount of drug applied (g) | 1360.8 (869.7) | 1238.6 (786.7) |
| Amount of drug applied per day (g) | 4.8 (2.2) | 5.1 (2.3) |
| Patients who used topical corticosteroids, n (%) | 224 (63.6) | 288 (56.9) |
Data are displayed as mean (SD) unless otherwise indicated. The pooled safety population includes all patients in QBA4‐2 and patients who received delgocitinib ointment in QBA4‐1. AD, atopic dermatitis; BSA, body surface area; IGA, Investigator’s Global Assessment; mEASI, modified Eczema Area and Severity Index; NRS, Numeric Rating Scale.